Company
Headquarters: Warsaw, Poland
Employees: 592
CEO: Mr. Jakub Julian Baran
€188.6 Million
EUR as of Dec. 1, 2021
US$213.2 Million
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $204.45 B |
| Danaher | $177.21 B |
| Siemens Healthineers AG | $63.84 B |
| DexCom, Inc. | $45.21 B |
| Lonza Group Ltd | $39.85 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Polski Bank Komórek Macierzystych S.A. operates an umbilical cord blood stem cell bank. The company operates through Afterbirth Tissues Banking B2C Services, Afterbirth Tissue Banking B2B Market, and R&D Activities segments. It engages in the processing and storage of human biological material for individual customers and business partners. The company provides diagnostic services; and operates one day hospital and a cell and tissue bank. It also operates diagnostic laboratory and ultrasound scan clinics; operates web portal and provides marketing activities; and conducts research activities. The company offers its services in Serbia, Sweden, Denmark, Ukraine, Germany, and the United States, as well as various Balkan countries and Egypt. Polski Bank Komórek Macierzystych S.A. was founded in 2002 and is based in Warsaw, Poland. Polski Bank Komórek Macierzystych S.A. operates as a subsidiary of AOC Health GmbH.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Polski Bank Komórek Macierzystych SA has the following listings and related stock indices.
Stock: FSX: 45Z wb_incandescent